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Abstract.  S100/~ produced in Escherichia coli from a 
synthetic gene (Van Eldik, L. J., J.  L. Staecker, and 
E  Winningham-Major.  1988. J.  Biol.  Chem. 
263:7830-7837)  stimulates neurite outgrowth and en- 
hances cell maintenance in cultures of embryonic 
chick cerebral cortex neurons. In control experiments, 
the neurite extension activity is reduced by preincuba- 
tion with antibodies made against bovine brain S100/L 
When either of the two cysteines in S100/3 are altered 
by site-directed mutagenesis, the resultant proteins 
maintain the overall biochemical properties of S100/~, 
but lose both the neurite extension and neuronal sur- 
vival activities. However, another S100/3 mutant, in 
which the relative position of one of the two cysteines 
was changed, had neurotrophic activity similar to that 
of the unmodified protein. These and other results in- 
dicate that (a) specific neurite extension activity and 
neuronal survival activity are two related activities in- 
herent to the S100/3 molecule; (b) a disulfide-linked 
form of S100/~ is required for full biological activity, 
and (c) the relative position of the cysteines can be 
modified. These data suggest potential in vivo roles 
for S100/~ in the development and maintenance of neu- 
ronal function in the central nervous system, and dem- 
onstrate the feasibility of the longer term development 
of selective pharmacological agents based on the 
S100/~ structure. 
T 
HE early development of  the vertebrate nervous system 
involves a complex set of events, including neuronal 
and glial cell proliferation,  migration and differentia- 
tion; neurite outgrowth and guidance; and establishment of 
appropriate  synapses. This program of development is fur- 
ther complicated by interactions  among different compo- 
nents of the nervous system. For example, specific extracel- 
lulax signals function as neurotrophic factors by stimulating 
neurite outgrowth and/or enhancing neuronal survival. Iden- 
tification and characterization of factors that have neurotro- 
phic activity are important steps in understanding the molec- 
ulax mechanisms by which neuronal development and axonal 
growth are controlled. Many types of neurotrophic factors 
have been described, including ions, hormones, extracellu- 
lax matrix proteins, cell-cell adhesion proteins, growth fac- 
tors, and oncogenes (for reviews, see Greene, 1982; Berg, 
1984; Thoenen et ai., 1987; Walicke, 1989). One of the best 
characterized neurotrophic factors  is  nerve growth factor 
(NGF),' whose effects include maintenance of the differen- 
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tiated state of mature sympathetic and sensory neurons, en- 
hancement of survival,  promotion and guidance of neurite 
outgrowth, and regulation of levels of neurotransmitter syn- 
thesizing enzymes (for review, see Misko et al.,  1987). 
S100/3, a protein found in high levels in glial cells, has re- 
cently been found to have neurotrophic activity on central 
nervous  system  (CNS)  neurons  (Kligman  and  Marshal 
1985; Van Eldik et ai., 1988). S100/3 belongs to a family of 
proteins with primary sequence similarities (for reviews, see 
Donato, 1986; Van Eldik and Zimmer, 1988). The S100 fam- 
ily includes: S100o~ and S100/~ (Isobe and Okuyama, 1981); 
calpactin light chain (Gerke and Weber, 1985; Glenney and 
Tack,  1985; Hexham et al.,  1986); S100L (Glenney et al., 
1989); proteins that are elevated in patients with cystic fibro- 
sis and rheumatoid arthritis (CF antigen [Dorin et al., 1987], 
MRP-8 and MRP-14 [Odink et al.,  1987]); and predicted 
protein sequences deduced from RNAs that are expressed in 
high levels in differentiated, transformed, or growth factor- 
treated cells (calcyclin [Calabretta et al., 1986; Ferrari et al., 
1987; Murphy et al.,  1988], 18A2 [Jackson-Grusby et al., 
1987], 42A and 42C [Masiakowski and Shooter, 1988], p9Ka 
[Baxraclough et al., 1987], pEL98 [Goto et al., 1988]). The 
observation that expression of members of the S100 family 
is altered during cell growth, differentiation,  and in certain 
diseases, suggests that they may play regulatory roles in these 
processes. 
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roles of many of the members of the S100 family, a disulfide- 
linked, probably dimeric form of S100/3 has been reported 
to stimulate neurite outgrowth in primary cultures of cere- 
bral cortex neurons (Kligman and Marshak, 1985; Van Eldik 
et al.,  1988),  in a  neuroblastoma cell line (Kligman and 
Hsieh,  1987),  and in organotypic cultures of spinal cord/ 
ganglia (our unpublished observations).  The observation that 
a dimeric form of S100/3 has neurite extension factor (NEF) 
activity, coupled with the presence of extracellular S100/3 in 
brain (Shashoua et al., 1984) and glial cell cultures (Suzuki 
et al., 1987; Van EMik and Zimmer, 1987), raises the possi- 
bility that during development of the nervous system, S100/3 
might be released from glial cells and act in a paracrine fash- 
ion to stimulate neurite outgrowth. The potential importance 
of S100B as a neurotrophic factor is also indicated by its lo- 
calization in the developing nervous system during the time 
of elongation of neuronal processes (Zomzely-Neurath and 
Walker,  1980; Van Hartsveldt et al., 1986; our unpublished 
observations). 
To develop the necessary reagents for addressing the long 
term question of how S100/3 may be involved in neuronal de- 
velopment and maintenance, we previously synthesized a 
gene coding for S100/3, expressed the gene in Escherichia 
coli, and produced protein (termed VUSB-1) by recombinant 
DNA technology (Van Eldik et al.,  1988).  We found that 
VUSB-1 preparations have NEF activity on embryonic chick 
cerebral  cortex neurons,  whereas  preparations  of E.  coli 
transformed with the vector lacking the S100/~ gene do not 
have NEF activity. We also showed that VUSB-1  prepara- 
tions lose NEF activity when treated with reducing agents, 
or when purifications are done in the presence of reducing 
agents,  consistent with previous data (Kligman and Mar- 
shak,  1985) that indicated that the NEF activity of bovine 
brain S100/3 requires a disulfide form of the protein. This ap- 
parent requirement for a disulfide linkage to function as a 
neurotrophic factor is intriguing in light of  the fact that S100/3 
proteins isolated from different species and tissues (Isobe 
and Okuyama,  1981; Kuwano et al.,  1984;  Jensen et al., 
1985;  Marshak  et  al.,  1985)  have  invariant cysteines at 
residues 68 and 84. In addition, S100/3 is the only member 
of the S100 family of proteins that has cysteines at both of 
these positions in the amino acid sequence; all other mem- 
bers have a valine at the position analogous to cysteine 68. 
The mechanisms by which S100/3 induces neurite exten- 
sion are not known, nor is it known what relative importance 
each cysteine has for formation of the biologically active di- 
meric  species.  Previous  studies  (Kligman and  Marshak, 
1985; Van Eldik et al., 1988) examined NEF activity under 
only one set of specific conditions: addition of S100/3 at the 
time the cells are placed into culture, and examination of the 
neurite extension response 20-24 h later.  No data are avail- 
able about the effect of varying the time of exposure of cells 
to S100/3. It is also unknown if  purified S100/3 affects survival 
of CNS neurons, similar to the effects of NGF on peripheral 
neurons. Combining recombinant DNA-based methods for 
the production of S100/3 proteins that differ in their cysteine 
content with selective assays for the analysis of NEF activity, 
we have begun to address some of these questions. In this re- 
port,  we described studies that:  (a)  analyze the effects of 
VUSB-1  on neurite extension under defined sets of condi- 
tions; (b) examine the ability of  VUSB-1 to enhance neuronal 
maintenance in cerebral cortex cultures; and (c) test directly, 
by site-directed mutagenesis/protein engineering experiments, 
the contribution of the cysteine residues to neurotrophic ac- 
tivity. 
Materials and Methods 
NEF  Activity Assays 
Chick cerebral cortex neurons were prepared and NEF activity of VUSB-1 
constructs was assayed as previously described (Van Eidik et al., 1988) ex- 
cept for the following modifications: (a) cells were plated at a density of 
11,500 cells/cm2; and (b) cells were examined by phase-contrast micros- 
copy after 24 h and scored positive if the length of the neurite(s) was equal 
to or greater than the diameter of the cell body. The percent neurite exten- 
sion was calculated as the percentage of neurite-bearing cells. Results are 
expressed as the mean +  SEM of the percentage of neurite-bearing cells 
from eight fields (4 fields/well; duplicate wells scored). 
The time dependence of the NEF assay was analyzed by two types of ex- 
periments. In the first experiments, the cells were placed into culture for 
various lengths of time in bioassay medium (Ham's F12 containing insulin 
[5/~g/ml], transferrin [5 #g/ml], progesterone [20 nM], sodium selenite [30 
nM], putrescine [100/zM], penicillin [100 U/ml], and streptomycin [100 
t~g/ml]), and then fresh medium with or without VUSB-1 was added. NEF 
activity was scored 24 h after the addition of fresh medium. In the second 
experiments, cells were allowed to attach to the tissue culture dish for 2 h, 
at which time (time 0) VUSB-1 was added to the cultures. At various time 
points thereafter, the VUSB-I was removed by adding fresh medium without 
VUSB-I to the cultures. The controls did not receive VUSB-1 at time 0, but 
received a  medium change at each of the time points. NEF activity was 
scored 24 h after each medium change. 
Neuronal Cell Survival Assay 
Cerebral cortex neurons were prepared from 7-d chick embryos as described 
above and placed into culture in the presence or absence of VUSB-1.2 h 
later (to allow for cell attachment), the number of cells in duplicate wells 
(4 fields/well) were counted, and this number represented the 100% value. 
The number of cells present at 24, 48, 72, and 96 h after plating was deter- 
mined, and the ratio of cells present at each time point to the number of 
cells present at 2 h was calculated. Medium was not changed during the 96-h 
assay period. 
Preparation of VUSB-1  for NEF  Assays 
Preparation of VUSB-1 with retention of NEF activity was done as previ- 
ously described (Van Eldik et al., 1988), except that samples from the DE52 
column were filter-sterilized but not dialyzed before storage at -80°C. In 
all experiments comparing the activity of VUSB-I and mutant constructs, 
the proteins were prepared and analyzed for activity on the same day. 
Site-directed Mutagenesis of VUSB4 
Site-directed mutagenesis was done by the cassette mutagenesis procedure 
essentially as described by Craig et al. (1987)  by taking advantage of the 
unique restriction enzyme sites that had been designed into the synthetic 
S100B gene (Van EIdik et al.,  1988).  We cleaved the gene (while resident 
in the vector) by using two different restriction enzyme sites flanking cys- 
teine 68 and cysteine 84.  Synthetic, double-stranded oligonucleotide cas- 
seres containing the desired nucleotide changes and containing ends that 
were complementary to the restriction enzyme sites used to cleave the gene 
were then prepared. The oligonucleotide cassettes used in these experiments 
are shown in Fig. 6 A. Mutants containing single cysteine changes (C68A, 
C68V, C68S, C84A, C84S) were prepared by ligating the pbosphorylated 
cassettes into the pVUSB-I vector (Van Eldik et al.,  1988) that had been 
cleaved with either StyI/Sfil (C68A, C68S, C68V) or Sfi I/Hind 3 (C84A, 
C84S). Mutants lacking both cysteine residues (C68V84A, C68V84S) were 
prepared by using an Eco RI/Sfi I fragment isolated from the plasmid con- 
raining the C68V gene (pC68V). This fragment was inserted into Eco RI/ 
Sfi I-cleaved plasmids containing either the C84A or C84S genes. The 
$62C68V mutant was prepared by iigating the phospborylated cassette into 
pC68V cut with Sty I and Sal I. This approach allowed insertion of cassettes 
in the correct orientation and reading frame. 
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et al., 1988),  and colonies were screened for the presence of the mutations 
by restriction mapping. To facilitate screening of clones, the cassettes for 
C68A, C68S, and C68V contained a new Dde I site, while the cassette for 
$62C68V had the Dde I site deleted. The cassettes for C84A and C84S con- 
rained a new Pst I site and FOk I site, respectively. After selection  of  positive 
constructs, the mutant constructs were characterized by detailed restriction 
enzyme mapping and/or nucleic acid sequencing as described (Van Eldik 
et al. 1988).  Fig. 6 B shows the nucleotide differences  between VUSB-I and 
the eight mutants used in this study. 
Proteins expressed from the mutant constructs were purified as previ- 
ously described (Van Eldik et al.,  1988).  Mutations in the proteins were 
verified by amino acid analysis, and some constructs were also character- 
ized by limited amino acid sequence analysis as described (Van Eldik et al., 
1988).  The mutant preparations analyzed by amino acid sequence were 
composed of  a mixture of molecules that had either retained or lost the initi- 
ator methionine at the amino terminus, similar to what we had previously 
found  (Van  Eidik  et  ai.,  1988)  with  VUSB-I  preparations  (results not 
shown). Also, the mobility of  the mutant proteins in SDS gels and the levels 
of expression of the mutant proteins ('~4 rag/liter of culture) were similar 
to those previously found for VUSB-1  (Van Eldik et al.,  1988). 
Immunochemical Analyses 
Rabbit antisera against bovine brain SI00/~ were characterized (Zimmer and 
Van Eldik,  1987)  and immunoblot analyses of SDS-polyacrylamide gels 
were done (Van Eldik and Wolchok, 1984) as previously described. For im- 
munoprecipitation experiments, VUSB-I was incubated for 1 h on ice with 
buffer A alone (20 mM Tris-HCl, pH 7.4, 0.3 M NaCI), with normal rabbit 
IgG (l:10 dilution), or with rabbit anti-Sl00~ IgG (1:10 dilution).  Protein 
A-Sepharose (Pharmacia Fine Chemicals, Piscataway,  NJ) was then added 
(100 #1 of a  1:1  slurry of resin and buffer A), and the mixtures were in- 
cubated on ice for 30 min. After centrifugation at 13,000 g for 5 min, the 
supernatant was assayed for NEF activity as described above. 
Protein Determinations 
Protein concentrations were determined by the method of Lowry et al. 
(1951) using BSA as a standard. 
Results 
Effects of VUSB4 on Neurite Extension 
Fig. 1 shows a representative example of the effect of VUSB- 
1 on chick cerebral  cortex  neurons.  Cerebral  cortex  cells 
from 7-d chick embryos were placed into culture in bioassay 
medium in poly-L-lysine-coated, 24-well plates.  The cells 
attached to the dish surface by 2-3 h after plating, and cell 
viability was >98%  by trypan blue exclusion.  After 24 h, 
cells cultured in bioassay medium alone (Fig.  1 A) showed 
minimal  neurite  extension  (only 2-12%  of the  cells  were 
positive for neurite extension). In contrast, cells cultured in 
the presence of VUSB-1 for 24 h (Fig. 1 B) showed a vigor- 
ous neurite extension response. The morphology of the cells 
Figure 1. Effect of VUSB-1 on chick cerebral cortex neurons. A shows two examples of negative controls,  where cells were cultured for 
24 h in bioassay medium alone. Similar results are seen when cells are cultured in the presence of extracts of E. coli transformed with 
the vector lacking the S10015 gene. B shows two examples of cells cultured in the presence of VUSB-1 preparation  (142 #g/ml) for 24 h. 
Note that most of the cells respond by elaborating long nenrites.  Bar, 50 #m. 
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Figure 2. Time dependence of the NEF activity of 
VUSB-1. In A, the effect of adding VUSB-1 to the 
cultures at various times was examined. Cells were 
cultured  for various  lengths of time in bioassay 
medium, and  then  fresh  medium  without  (open 
bars) or with 96/~g/ml VUSB-1 (solid bars) was 
added at each time point. The percentage of cells 
with neurites was determined 24 h after each medi- 
um change. In B, the effect of removing VUSB-1 
from the cultures at various times was examined. 
Cells were cultured for 2 h in bioassay medium, 
at  which  time (time  0)  medium without  (open 
bars) or with 96/~g/ml  VUSB-1 (solid bars) was 
added. At each time point thereafter, fresh bioas- 
say medium  was added  and  the  percent  neurite 
extension was determined 24 h after the medium 
change. 
was heterogeneous, with some cells exhibiting monopolar or 
bipolar processes and  others exhibiting  multipolar  and/or 
branching processes. 
The time dependency of the NEF activity was examined 
by adding or removing VUSB-1 to or from the cultures at var- 
ious times, and analyzing the subsequent effects on neurite 
extension (Fig. 2). When VUSB-1 was added at the time of 
cell plating (time 0) or at 3, 6, or 9 h after plating, there was 
no  apparent  difference  in  the  neurite  extension  response 
scored 24  h  after VUSB-1  addition  (Fig.  2  ,4).  However, 
when VUSB-1 was added at 12, 24,  or 48 h after the ceils 
were plated and then scored 24 h  after VUSB-1  addition, 
there was a decrease in the percentage of cells with neurites. 
We also examined the length of time that cells must be ex- 
posed to VUSB-1 to respond in the NEF assay. In these ex- 
periments (Fig. 2 B), cells were allowed to attach to the cul- 
ture  dishes  for 2  h,  at which  time (time 0)  VUSB-1  was 
added. At various time points thereafter, the VUSB-1 was re- 
moved by addition of fresh medium, and neurite extension 
scored 24  h  later.  The  results  show  that cells exposed to 
VUSB-1 for <1.5 h show a neurite extension response similar 
to control cells.  However, continuous exposure of cells to 
VUSB-1 for 24 h is not required for a maximal response; in 
fact, the response of cells exposed to VUSB-1 for 2, 6, or 24 h 
was indistinguishable.  These data indicate that there is an 
early period during which the presence of VUSB-I is essen- 
tial for maximum neurite extension,  and that once the re- 
sponse is initiated,  the presence of VUSB-I in the cultures 
is no longer required. 
As shown in Fig. 3, addition of VUSB-1 resulted in a dose- 
dependent  increase  in  the  percent  of cells  with  neurites, 
reaching a plateau value of 51% in this experiment. We gen- 
erally see maximum responses of ~50-60% positive cells. 
The difference in the neurite extension response between con- 
trol cultures and cultures treated with VUSB-1 (at the highest 
concentrations) was determined to be significant at the  1% 
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Figure 3.  Dose dependence  of the NEF activity of VUSB-1. The 
percentage of  cells with neurites was determined 24 h after the addi- 
tion of increasing amounts of VUSB-1 preparation to the cultures. 
Figure 4.  Analysis of VUSB-I preparation  by gels and immuno- 
blots. A shows a Coomassie Blue-stained,  15 % (wt/vol) acrylamide- 
SDS gel containing 1 mM EDTA. Samples were run in the absence 
of reducing agent. Lane 1, molecular weight standards of 68,000, 
43,000, 30,000, 20,000, and 14,000. Lane 2, DE52 eluate of E. coli 
preparations transformed with the vector lacking the S100/~ gene. 
Lane 3,  DE52  eluate  of E.  coil preparations  transformed  with 
pVUSB-I (containing the  $100/~ gene).  B shows an immunoblot 
analysis of a similar gel that had been transferred to nitrocellulose 
and incubated with antibodies to $100#. Lane I contains prestained 
molecular weight standards of 68,000, 43,000, 30,000, 20,000, and 
14,000. No reactivity with anti-Sl00~  antibody is observed in the 
DE52 eluate of E. coil preparations  transformed  with the vector 
lacking the $100/~ gene (lane 2). The VUSB-1 preparation (lane 3) 
shows reactivity with anti-S100/~ antibody, with intense staining of 
monomeric VUSB-1 and faint staining of  dirueric forms of  V  USB-1. 
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tive cells obtained with bioassay media alone or with extracts 
ofE. coli transformed with a vector lacking the VUSB-1 gene 
ranged from 2 to 12%. In the experiment shown in Fig. 3, 
the concentration of the VUSB-1  preparation required for 
half-maximal stimulation was •15  #g/ml. Among different 
experiments and different VUSB-1 preparations, we have seen 
a two- to threefold variation in the concentration of VUSB-1 
required for half-maximal stimulation. While this concentra- 
tion of protein is high compared to other neurotrophic fac- 
tors, it should be noted that the VUSB-1 preparation used for 
NEF assays is a partially purified, DE52 eluate that contains 
primarily monomeric VUSB-1 and only a small proportion 
of dimeric VUSB-1, as analyzed by immunoblots (Fig. 4). 
The specificity of the NEF activity was addressed further 
by examining the activity of VUSB-1 preparations after incu- 
bation with antibodies to S100/~. As described in Materials 
and Methods, VUSB-1 was incubated with anti-S100/~ IgG, 
complexes were precipitated with Protein A-Sepharose, and 
the resultant supernatant was assayed for NEF activity. Table 
I  shows that incubation of VUSB-1 with antibodies direct- 
ed against S100/3 reduced the neurite extension response, 
whereas incubation of VUSB-1 with normal rabbit IgG did 
not reduce the response. These data provide further evidence 
that the active NEF is VUSB-1 and not a contaminant in the 
preparation. 
Effect of VUSB-I on Cell Maintenance 
We found that VUSB-1 enhanced the maintenance of neurons 
in  addition to  stimulating  neurite extension (Fig.  5).  For 
these experiments, chick cerebral cortex neurons were cul- 
tured in the presence or absence of VUSB-1 for 24, 48, 72, 
and 96 h, and the number of neurons present were counted 
after each time period. During the first 24 h in culture, the 
number of cells present in the control cultures and the cul- 
tures containing VUSB-1 were similar (Fig. 5). The cells ap- 
peared healthy with little or no cell degeneration or cellular 
debris. However, after 96 h, over 80% of the cells in control 
cultures had degenerated. In contrast, addition of VUSB-1 
to the cultures increased the precentage of cells remaining in 
the culture dishes.  The ability of VUSB-I to enhance cell 
maintenance was dose-dependent over a similar range as the 
NEF activity (data not shown). Other proteins tested, such 
as calmodulin or oMactalbumin, did not enhance cell main- 
tenance (data not shown). 
Effect of Cysteine Mutants on NEF Activity 
Previous data (Kligman and Marshak,  1985; Van Eldik et 
al., 1988) suggested that the NEF activity of $100/3 requires 
Table I. NEF Activity is Inhibited by Anti-SlO0 IgG 
Percentage of cells with nenrites 
Experiment  1  Experiment 2 
VUSB-I Alone  45  +  6  49  -t-  7 
VUSB-I  +  Normal rabbit IgG  47  +  3  51  +  3 
VUSB-I  +  Anti-Sl00/~ IgG  16  +  4  9  +  4 
lmmunoprecipitations  were done as described  in Materials and Methods. The 
results  from two separate experiments  are shown. 
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Figure 5. The effect of VUSB-I on survival of chick cerebral cortex 
neurons. Cells were cultured in the presence of 163/zg/ml VUSB-1 
preparation (circles) or bioassay medium alone (triangles), and the 
percentage of cells remaining in the cultures at various time points 
was determined. 
a disulfide form of the protein. S100/3 contains cysteines at 
residues 68 and 84 (see Fig. 6), but how the disulfide bonds 
are arranged to produce functional NEF is unknown.  We 
have examined the relative contribution of cysteine 68 and 
cysteine 84 to the NEF activity of VUSB-1 as an initial step 
to address the structural requirements for NEF activity. As 
described in Materials and Methods, we prepared by site- 
directed mutagenesis seven mutant VUSB-1 proteins (termed 
C68A, C68S, C68V, C84A, C84S, C68V84A, C68V84S), in 
which cysteine 68 was changed to alanine, serine, or valine; 
cysteine 84 was changed to alanine or serine; or both cys- 
teines were changed (cysteine 68 to valine and cysteine 84 to 
alanine or serine). The location and description of the muta- 
tions in the seven proteins are in Fig. 6. The presence of the 
appropriate mutation was confirmed by one or more of the 
following:  restriction  enzyme  mapping,  DNA  sequence 
analysis, or amino acid compositional analysis. 
The mutant proteins were purified for NEF activity assays 
exactly as VUSB-1, and tested for their ability to stimulate 
neurite outgrowth. Fig. 7 shows that mutants lacking either 
cysteine 68  or  cysteine  84  (C68A,  C68S,  C68V,  C84A, 
C84S) showed a significant decrease in NEF activity, with 
little or no activity at any dose tested (significant at the 5 % 
level for the highest protein concentrations In =  6 or 7 de- 
pending on the mutant] using an unranked sign tes0. Simi- 
larly, the mutants lacking both cysteine 68 and cysteine 84 
(C68Vg4A, C68V84S) were inactive compared to VUSB-1. 
The absence of a cysteine at position 68 or 84 also resulted 
in a  loss  in the ability to enhance cell survival (data not 
shown). These data suggest that the presence of  both cysteine 
residues is necessary for full activity. 
To address whether there is flexibility in the exact location 
of the cysteine residues for NEF activity, we prepared an- 
other mutant designated $62C68V. In this mutant, serine 62 
was changed to cysteine, and cysteine 68 was changed to va- 
line (cf., Fig.  6).  Thus, this mutant still has two cysteine 
residues, but the invariant cysteine that is normally found at 
residue 68 has been moved to residue 62.  We found that 
$62C68V stimulated neurite extension (Fig. 8) and enhanced 
cell maintenance (data not shown) similar to VUSB-1. These 
data suggest that the structural requirements for NEF activity 
are somewhat flexible in that the relative position of the two 
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C68A Cassette 
Styl  Sfil 
Ddel  A68 
5'  CTTGGACTCAGACGBTGACGGTGAAGCGGACTTTCAGGAGTTTATGGCCTTCG  3' 
3'  CTGAGTCTGCCACTGCCACTTCGCCTGAAAGTCCTCAAATACCGGA  5' 
B 
C68S Cassette 
Styl  Sfil 
Ddel  $68 
5'  CTTGGACTCAGACGGTGACGGTGAATCCGACTTTCAG6AGTTTATGGCCTTCG  3' 
3'  CTGAGTCTGCCACTGCCACTTAGGCTGAAAGTCCTCAAATACCGGA  5' 
C68V Cassette 
Styl  Sfil 
Odel  V68 
5'  CTTGGACTCAGACGGTGACGGTGAAGTCGACTTCCAGBAGTTTATGGCCTTCG  3' 
3'  CTGAGTCTGCCACCGTCACTTCAGCTGAAGGTCCTCAAATACCGGA  5' 
C68A 
C68S 
C68V 
C84A 
CB4S 
C68V84A 
C68V84S 
$62C68V 
Styl  Sall 
I  6o  I  70 
thr  leu  asp  ser  asp  gly  asp  gly  glu  cys  asp  phe  gln  glu  phe met  ala 
ACC  TTG GAC  TCT  GAC  GGT  6AC  GGT  GAA TGC  6AC  TTC  CAG  GAS TTT ATG  GCC 
A  GCG  T 
A  C  T 
A  GT 
A  6T 
A  GT 
GC  GT 
C84A Cassette 
Sfil  Hind3 
Pstl  A84 
5'  TGGCCATGATAACTACTBCA6CGCATGAGTTCTTCGAACATGAATA  3' 
3'  AGCACCGGTACTATTGATGACGTCGCGTACTCAAGAAGCTTGTACTTATTCGA  5' 
Sfil  Hind3 
I  Bo  90  I 
phe  val  ala  met  ile  thr  thr  ala  cys  his  glu  phe  phe  glu  his  glu 
TTC  GTG  GCC  AT6 ATA ACT  ACT  GCA  TGC  CAT  GAG  TTC  TTC  GAA CAT  GAA TA 
C68A 
C68S 
C84S Cassette  C68V 
Sfil  Hind3  C84A  GCG 
Fokl  S84  C84S  C  T 
5'  TGGCCATGATAACTACTGCATCCCATGAGTTCTTTGAACATGAATA  3'  C68V84A  GCG 
3'  AGCACCGGTACTATTGATGACGTAGGBTACTCAAGAAACTTGRACTTATTCGA  5'  C68V84S  C  T 
$62C68V 
$62C68V Cassette 
Styl  Sal I 
C62 
5'  CTTGGACTGCGACGGTGACGGTGAAG  3' 
3'  CTGACGCTGCCACTGCCACTTCAGCT  5' 
Figure 6. Site-directed mutagenesis of VUSB-I. A shows the nucleotide sequences of the double-stranded, oligonucleotide cassettes used 
for the preparation of VUSB-1 mutants. The positions of the codon changes at residues 68, 84, and 62, and the resultant changes in amino 
acids are indicated (A, alanine; S, serine; V, valine; C, cysteine). The positions of the new restriction enzyme sites incorporated for screening 
purposes are shown, with the sites delineated by solid lines above or below the sequence.  The restriction enzymes listed on the left and 
fight of the cassettes  are the enzymes that are complementary  to the ends of the cassettes.  B shows the nucleotide  sequence  changes of 
the eight VUSB-1  mutants used in this study. The relevant portion (residues 59-91) of the amino acid sequence of VUSB-1  is shown on 
the top line, with the corresponding nucleotide  sequence on the second line.  For the mutants, only nucleotide  residues that are different 
from the VUSB-1  sequence are shown. The positions of selected  restriction enzymes used in the construction of the mutants are shown. 
cysteine residues can be altered without significantly dimin- 
ishing the neurotrophic activity. 
Discussion 
In this report, we have analyzed the ability of a recombinant 
S100/~  (VUSB-1) to stimulate neurite outgrowth from chick 
embryo cerebral cortex neurons, and have demonstrated that 
VUSB-1  also enhances neuronal maintenance in culture. In 
addition,  we have shown by site-directed mutagenesis/pro- 
tein engineering  approaches that both cysteine residues of 
VUSB-1 are important for neurite extension and cell survival 
activity, and that the relative position of the two cysteines can 
be altered without loss of activity. These data provide further 
evidence  to  support the hypothesis  that a  disulfide-linked 
form of S100fi may act as a neurotrophic factor in the CNS, 
and indicate the potential for development of pharmacologi- 
cally useful reagents based on the S100fi  structure.  These 
results also provide a foundation for future studies into the 
molecular mechanisms by which S100~ affects neuronal de- 
velopment and maintenance. 
We previously reported the synthesis and expression of a 
gene coding for S100/~,  and showed that the expressed pro- 
tein (VUSB-1) had NEF activity on embryonic chick cerebral 
cortex  neurons  in  culture  (Van  Eldik  et  al.,  1988).  The 
studies reported here extend this previous work by further 
characterizing the effects of VUSB-1  on neurite extension, 
and by analyzing the ability of VUSB-1 to enhance cell main- 
tenance  in  this  bioassay  system.  The bioassay  we used  is 
similar to that established by Kligman (1982), whose labora- 
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Figure  7.  NEF activity of cysteine mutants. The NEF activity of 
VUSB-1 and of mutants with changes at either eysteine 68 (C68A, 
C68S,  C68V), cysteine  84  (C84A,  C84S),  or  both  cysteines 
(C68V84A, C68V84S) was determined.  VUSB-1 (solid circles), 
C68A (X), C68S (open triangles),  C68V (open squares),  C84A 
(solid squares), C84S (+), C68V84A (solid triangles), C68V84S 
(open circles). For clarity, the SEM bars are indicated only for the 
VUSB-1. The SEM for the mutants ranged from 3 to 8 %. 
tory subsequently showed its utility for analysis of the NEF 
activity of bovine brain S100/~ preparations (Kligman and 
Marshak, 1985). Similar to these previous studies with brain 
S100/3, we find that VUSB-1 preparations stimulate neurite 
outgrowth in a dose-dependent manner. However, it should 
be noted that the effective  concentration of the VUSB-1 prep- 
aration required for half-maximal stimulation is higher than 
the effective  concentration of purified brain NEF (125 ng/ml; 
cf., Kligman and Marshak,  1985); in addition, the concen- 
trations of both VUSB-1 and brain S100/~ preparations re- 
quired for NEF activity are high compared to other neuro- 
trophic factors. This apparent discrepancy can be explained 
in part by the fact that the VUSB-1 preparation used in the 
present studies, as well as the brain NEF used by Kligman 
and  Marshak  (1985),  are mixtures of monomeric and di- 
meric S100/$ forms, as analyzed by SDS-polyacrylamide  gels 
(cf., Fig. 4). Because S100/~ can form both covalent and non- 
covalent dimers,  and  because the  structure  of the  active 
disulfide-linked species has not been demonstrated, it is not 
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Figure R Effect of changes in the position of the cysteine residues 
of VUSB-I. A mutant ($62C68V) where cysteine 68 was m~ed to 
position 62 was constructed as described in Materials and Methods. 
The NEF activity of  VUSB-1 (triangles) and $62C68V (circles) was 
determined. 
known how much of the protein migrating as a dimer exists 
in the active conformation. Thus, the biologically functional 
molecule may comprise only a fraction of  the VUSB-1 prepa- 
ration, and determination of the effective concentration will 
require future studies to purify to homogeneity the active 
disulfide-linked species of VUSB-1. 
Even though the VUSB-1 used in these studies is a par- 
tially  purified protein  fraction,  several  lines  of evidence 
demonstrate that the NEF activity is a property of  the VUSB- 
1 molecule and not a result of a contaminant in the prepara- 
tion.  First,  NEF activity is diminished after incubation of 
VUSB-1 with antibodies against S100#, but not by incubation 
of VUSB-1 with normal rabbit IgG. Second, extracts of E. 
coil transformed with a vector lacking the VUSB-1 gene do 
not contain NEF activity. Third, preparation of VUSB-1 in 
the presence of  reducing agents results in a loss of NEF activ- 
ity. Fourth, alteration of a single amino acid by site-directed 
mutagenesis of either of the cysteine residues results in a de- 
crease in NEF activity. 
The molecular mechanisms by which VUSB-1 stimulates 
neurite extension are not known. VUSB-1 could act as an at- 
tachment or adhesion factor, similar to extracellular matrix 
proteins or cell adhesion molecules (for reviews, see Edel- 
man,  1986;  Walicke,  1989).  However, this possibility ap- 
pears unlikely since the neurotrophic effects of VUSB-1 in 
the cerebral cortex bioassay are not mimicked by addition of 
laminin, fibronectin, collagen, or FCS (data not shown). 
Removal of  VUSB-1 from cultures at various times showed 
that the presence of VUSB-1 for the initial 2 h of culture was 
sufficient to elicit a maximum response 24 h later (cf., Fig. 
2 B). This temporally limited dependency is consistent with 
a potential receptor-mediated mechanism. A mechanism in- 
volving  VUSB-1  interaction  with  a  specific  cell  surface 
receptor would be analogous to the mechanism of action of 
several other neurotrophic factors (for examples, see Misko 
et al.,  1987; Rodriquez-Tebar and Barde, 1988; Sutter et al., 
1979; Walicke, 1989). Although no data are yet available on 
whether S100 receptors are present on chick cerebral cortex 
neurons, there have been reports of  Sl00 binding sites on var- 
ious types of neuronal membranes (Donato, 1977; Donato et 
al.,  1975).  Defining the mechanisms by which S100fl inter- 
acts with the neuronal cell, and the critical molecular events 
within the neuronal cell that mediate neurite outgrowth are 
areas of research to be addressed in future studies. 
In addition to stimulating neurite outgrowth, VUSB-1 also 
increases the percentage of cells remaining  in the culture 
dishes as a function of time in culture. While cell viability 
was not measured directly in these long-term (96-h) culture 
experiments,  our  data  strongly  suggest  that VUSB-1  en- 
hances survival of  the neuronal cells in culture. These results 
are consistent with studies of several other neurotrophic fac- 
tors that stimulate both neurite extension and cell survival 
(for examples,  see Thoenen et al.,  1987;  Hefti and Will, 
1987; Walicke, 1989). However, our results are in disagree- 
ment with those of Kligman (1982), who reported that a par- 
tially purified preparation of bovine brain NEF did not en- 
hance cell survival in a cerebral cortex bioassay. The reasons 
for this discrepancy are not clear, although it may result from 
differences in purification protocols or the source of the pro- 
tein. We have shown here that VUSB-1 and $62C68V prepa- 
rations  that  stimulate  neurite extension also  enhance cell 
maintenance, and mutant constructs that are inactive in the 
Winningham-Major  et al. Neurotrophic Activity of Recombinant SlOOs  3069 NEF assay are also inactive in the cell survival assay. These 
data provide further evidence that the ability to stimulate 
neurite extension and enhance cell survival are both proper- 
ties of  the VUSB-1 molecule, and suggest that there are simi- 
lar structural or mechanistic constraints on the protein for 
both activities. 
To begin analysis of the structural features of VUSB-1 that 
are required for neurotrophic activity, we tested the relative 
contribution of cysteine 68 and cysteine 84. To minimize the 
potential  effects  of mutation  on  indirect,  conformational 
aspects of structure, conservative substitutions were made: 
cysteines were replaced with serine or alanine (C68S, C68A, 
C84S, C84A). Serine was chosen because of its similarity to 
cysteine in structure and solvation properties,  and alanine 
was chosen because of its small size and neutral charge. In 
addition, because all the members of the S100 family (except 
S100~) contain a valine at the position analogous to cysteine 
68, we also constructed a mutant with eysteine 68 changed 
to valine (C68V).  While a detailed structural analysis of the 
proteins would be required to determine how particular mu- 
tations affect localized conformational changes, the mutant 
proteins maintained the overall biochemical properties of 
S100~,  allowing their isolation by the same protocol used 
for the unmodified protein.  However,  these mutants with 
changes at either cysteine 68 or cysteine 84 were unable to 
stimulate neurite extension or enhance neuronal survival. 
These data indicate that the linear amino acid sequence alone 
is not sufficient for neurotrophic activity, but that secondary 
structural features; i.e., disulfide bonds, are important for 
both neurite extension and neuronal survival activities. In 
addition, the fact that both cysteine residues are necessary 
for  biological  activity  suggests  an  involvement  of both 
residues in the disulfide linkage of the active species of the 
protein. Three possible active disulfide forms that would be 
consistent with our results are an interchain dimer with one 
disulfide linkage between heterologous cysteines (cysteine 
68/cysteine 84) or two disulfide linkages between heterolo- 
gous  (cysteine  68/cysteine  84)  or  homologous  (cysteine 
68/cysteine 68 and cysteine 84/cysteine 84) cysteines. 
To begin to analyze the secondary structural constraints on 
the protein for neurotrophic activity, we tested the effect of 
changing the relative position of the two eysteines in the lin- 
ear amino acid sequence. Because a three-dimensional struc- 
ture for S100/~ is not available, we used the structure of the 
vitamin D-dependent calcium binding protein (Szebenyi and 
Moffat, 1986) as a model in the design of the $62C68V  mu- 
tant (in which eysteine 68 was changed to valine and serine 
62 was changed to cysteine). The amino acid residues of 
S100~ postulated to be calcium liganding residues (aspartic 
acid 61, aspartic acid 63, aspartic acid 65, glutamic acid 67, 
aspartic acid 69, and glutamic acid 72) based on the EF hand 
model (Kretsinger, 1980) and on homology with the vitamin 
D-dependent calcium binding protein  structure (Szebenyi 
and Moffat,  1986)  encompass the region around residues 
61-72. While serine 62 and cysteine 68 are thought not to be 
involved in direct calcium binding, they comprise part of the 
loop structure of the postulated EF hand calcium binding site 
of S100~/. The probable proximity of serine 62 and cysteine 
68 in three-dimensional structure, as well as the structural 
similarity between cysteine and serine, made the position- 
ing of a cysteine at residue 62 a logical first choice. When 
$62C68V  was analyzed for neurotrophic activity, we found 
that the protein stimulated neurite extension and enhanced 
cell  maintenance in  a  manner  similar to  the  unmodified 
VUSB-1. These data suggest that, although two cysteines are 
required for activity, there is flexibility in the relative posi- 
tioning of the cysteine residues. 
The observation that the position of the cysteine residues 
in the linear sequence can be altered without significantly  di- 
minishing the neurotrophic activity provides additional op- 
tions for generating a population of VUSB-1 molecules with 
a more homogeneous secondary structure. In addition, this 
observation  has  important  pharmacological  implications. 
The ability to design synthetic neurotrophic agents based on 
the S100~ structure may allow the future development of re- 
agents potentially useful for nerve regeneration or selective 
maintenance of neuronal function. Altogether, our data pro- 
vide new insight into a potential role for S100/~ in the devel- 
opment and maintenance of neuronal function in the central 
nervous system. 
We thank Paul Matrisian, Augustine Smith, Wendy Gunnarsen, Rebecca 
Miller, Sandra Wolchok, and Scott Nottingham for their assistance in vari- 
ous aspects of these studies. We are grateful to D. Martin Watterson and 
Thomas Lukas for their helpful discussions and suggestions. 
These studies were supported in part by funds from the Muscular Dys- 
trophy Association and the Alzheimer's Disease and Related Disorders As- 
sociation (L.  Van Eidik),  National Cancer Institute predoctoral  training 
grant CAID592 (S. W. Barger and S, Coats), and National Cancer Institute 
postdoctoral training grant CA09592 and a Pharmaceutical Manufacturer's 
Association postdoctoral fellowship (both to F. Winningham-Major). 
Received for publication 1 June 1989 and in revised form 7 August 1989. 
References 
Barraclough, R., J. Savin, S. K. Dube, and P. S. Rndland. 1987.  Molecular 
cloning and sequence of the geue for pgKa, a cultured myoepithelial cell pro- 
tein with strong homology to S-100, a calcium binding protein. J. Mol. Biol. 
198:13-20. 
Berg,  D.  K.  1984.  New neuronal growth factors. Annu.  Rev.  Neurosci.  7: 
149-170. 
Calabretta, B., R. Battini,  L. Kaczmarek, J. K. de R/el, and R. Baserga. 1986. 
Molecular cloning of the eDNA for a  growth factor-inducible geue with 
strong homology to S-100, a calcium-binding protein. J. Biol.  Chem.  261: 
12628-12632. 
Craig, T.  A., D.  M.  Watterson, F. G.  Prendergast, J.  Haiech, and D. M. 
Roberts.  1987. Site-specific  mutagenesis of the a-helices of calmodulin. J. 
Biol.  Chem.  262:3278-3284. 
Donato, R. 1977. Solubilization  and partial characterization of the S 100 protein 
binding activity of synaptosomal particulate fractions. Y. Neurochem. 28: 
553-557. 
Donato, R.  1986.  S-100 proteins. Cell Calcium.  7:123-145. 
Donato, R., F. Michetti, and N. Miani.  1975.  Soluble  and membreue-buand 
S-100 protein  in cerebral  cortex  synaptosemes. Properties of the S-100 
receptor. Brain Res. 98:561-573. 
Dorin, J. R., M. Novak, R. E. Hill, D. J. H. Brock, D. S. Secher, and V. van 
Heyningen. 1987. A clue to the basic defect in cystic fibrosis from cloning 
the CF antigen gene. Nature (Lond.).  326:614--617. 
Edelman, G. M. 1986. Cell adhesion molecules in the regulation of animal form 
and tissue pattern. Aanu. Rev.  Cell Biol.  2:81-116. 
Ferrari, S., B. Calabretta, J. K. de Riel, R. Battini,  F. Gbezzo, E. Lauret, C. 
Griffin,  B. S. Emanuel, F. Gurrieri, and R. Baserga. 1987.  Structural and 
functional analysis of a growth-regulated gene, the human calcyclin. J. Biol. 
Chem.  262:8325-8332. 
Gerke, V., and K. Weber. 1985. The regulatory chain in the p36-kd substrate 
complex of viral tyrosine-specific protein kinases is related in sequence to 
the S-100 protein of glial cells. EMBO (Eur. MoL Biol.  Organ.) J. 4:2917- 
2920. 
Glenney, J. R., Jr., and B. F. Tack.  1985.  Amino-terminal sequence of p36 
and associated p l0: identification  of the site of tyrosiue phosphorylation and 
homology with S-100.  Proc. Natl. Acad.  Sci.  USA.  82:7884-7888. 
Glenuey, J. R., Jr., Kindy, M. S., and Zokas, L. 1989. Isolation of a new mem- 
ber of the S 100 protein family: amino acid sequence, tissue, and subcellular 
distribution. J.  Cell Biol.  108:569-578. 
Goto, K., H. Endo, and T. Fujiyoshi. 1988. Cloning of the sequences  expressed 
abundantly in established cell lines: identification  of a eDNA clone highly 
The Journal of Cell Biology, Volume 109,  1989  3070 homologous to S-100, a calcium binding protein. J. Biochem.  103:48-53. 
Hefti, F., and B. Will. 1987. Nerve growth factor is a nenrotrophic factor for 
forebraln cholinergic neurons: implications for Alzheimer's disease. J. Neu- 
ral Transm. 24:309-315. 
Hexham, J. M., N. F. Totty, M. D. Waterfield, and M. J. Crumpton. 1986. 
Homology between the subnnits  of S 100 and a 10kDa polypeptide associated 
with p36 of pig lymphocytes. Biochem.  Biophys. Res.  Commun.  134:248- 
254. 
Hyden, H., and L. Ronnhack. 1975.  Membrane-bound SI00 protein on nerve 
cells and its distribution. Brain Res.  100:615-628. 
Isobe, T., and T. Okuyama. 1981. The amino acid sequence of the ct subunit 
in bovine brain Sl00a protein. Fur. J.  Biochem.  116:79-86. 
Jackson-Grusby, L. L., J.  Swiergiel, and D. I.  H. Linzcr.  1987.  A growth 
related  mRNA in cultured mouse cells encodes a placental calcium binding 
protein. Nucleic Acids Res.  15:6677--6690. 
Jensen, R., D. Marshak, C. Anderson, T. Lukas, and D. M. Watterson. 1985. 
Characterization of human brain S 100 protein fraction:  amino acid sequence 
of SI00/~. J.  Neurochem.  45:700-705. 
Kligman, D.  1982.  Isolation of a protein from bovine brain which promotes 
neurite extension from chick embryo cerebral cortex neurons in defined 
medium. Brain Res.  250:93-100. 
Kligman, D., and D. R. Marshak. 1985.  Purification  and characterization of 
a neurite extension factor from bovine brain. Proc.  Natl. Acad.  Sci. USA. 
82:7136-7139. 
Kligman, D., and L. S. Hsieh. 1987.  Neurite extension factor induces rapid 
morphological  differentiation  of  mouse  neuroblastoma cells  in  defined 
medium. Dev.  Brain Res.  33:296-300. 
Kretsinger, R.  1980.  Structure and evolution of calcium modulated proteins. 
CRC Crit. Rev.  Biochem.  8:119-174. 
Kuwano, R., H. Usni, T. Maeda, T. Fukui, N. Yamanari, E. Ohtsuka, M. Ike- 
hara, and Y. Takahashi. 1984. Molecular cloning and the complete nucleo- 
tide sequence of cDNA to mRNA for SI00 protein of rat brain. Nucl. Acids 
Res.  12:7455-7465. 
Lowry, O. H., N. J. Rosebrough, A. L. Fan', and R. J. Randall. 1951. Protein 
measurement with the folin phenol reagent. J.  Biol. Chem. 193:265-275. 
Marshak, D. R., H. Umckawa, D. M. Watterson, and H. Hidaka. 1985. Struc- 
tural characterization of the calcium binding protein SI00 from adipose tis- 
-sue. Arch.  Biochem.  Biophys.  240:777-780. 
Masiakowski, P., and E. M. Shooter.  1988.  Nerve growth factor induces the 
genes for two proteins related  to a  family of calcium-binding proteins in 
PCI2 cells. Proc.  Natl. Acad.  Sci. USA. 85:1277-1281. 
Misko, T. P., M. J. Radeke, and E. M. Shooter.  1987.  Nerve growth factor 
in neuronal development and maintenance. J.  Exp. Biol. 132:177-190. 
Murphy, L. C., L. J. Murphy, D. Tsuynki, M. L. Duckworth, and R. P. C. 
Shin. 1988. Cloning and characterization of a cDNA encoding a highly con- 
served, putative calcium binding protein,  identified  by an anti-prolactin 
receptor antiserum. J.  Biol. Chem. 263:2397-2401. 
Odink, K., N. Cerletti, J. Bruggen, R. G. Clere, L. Tarcsay, G. Zwadlo, G. 
Gerhards, R. Schlegel, and C. Sorg.  1987.  Two calcium-binding proteins 
in infiltrate macrophages of rheumatoid arthritis.  Nature (Lond.). 330:80-82. 
Rodriquez-Tehar, A., and Y. A. Barde.  1988. Binding characteristics of brain- 
derived neurotrophic factor to its receptor on neurons from the chick em- 
bryo. J.  Neurosci.  8:3337-3342. 
Shasboua, V. E., G. W. Hesse, and B. W. Moore. 1984. Proteins of the brain 
extraceilular fluid:  evidence for release of SI00  protein. J.  Neurochem. 
42:1536--1541. 
Sutter, A., R. J. RiopeUe,  R. M. Harris-Warrick, and E. M. Shooter.  1979. 
Nerve growth factor receptors. Characterization of two distinct classes of 
binding sites on chick embryo sensory ganglia cells. J.  Biol. Chem. 254: 
5972-5982. 
Suzuki, F., K. Kato, T. Kato, and N. Ogasawara. 1987. S-100 protein in clonal 
astroglioma cells is released by adrenocorticotropic hormone and cortico- 
tropin-like intermediate-lobe peptide. J. Neurochem.  49:1557-1563. 
Szebenyi, D. M.  E., and K. Moffat.  1986.  The refined structure of vitamin 
D-dependent calcium-binding protein from bovine intestine. Molecular de- 
tails, ion binding, and implications for the structure of other calcium-binding 
proteins. J.  Biol. Chem. 261:8761-8777. 
Thoenen, H., Y.-A. Barde, A. M. Davies, and J. E. Johnson. 1987.  Neuro- 
trophic factors and neuronal death. Ciba Found. Syrup. 126:82-95. 
Van Eldik, L. J., and S. R. Wolchok. 1984. Conditions for reproducible detec- 
tion of calmodulin and S 100/3 in immunoblots. Biochem. Biophys. Res. Com- 
mun. 124:752-759. 
Van EIdik,  L. J., and D. B. Zimmer. 1987.  Secretion of S-100 from rat C6 
glioma cells. Brain Res. 436:367-370. 
Van EIdik,  L. J., and D. B. Zimmer. 1988. Mechanisms  of action oftbe Sl00 
family of calcium modulated proteins. In Calcium and Calcium Binding Pro- 
teins. C. Gerday, R. Gilles, and L. Bolis, editors. Springer-Verlag, Berlin. 
114-127. 
Van EIdik,  L. J., J. L. Staecker, and F. Winningham-Major. 1988. Synthesis 
and expression of a gene coding for the calcium-modulated protein SI00/~ 
and designed for cassette-based, site-directed mutagenesis. J. Biol. Chem. 
263:7830-7837. 
Van Hartsveldt, C., B. Moore, and B. K. Hartman. 1986.  Transient midline 
raphe glial structure in the developing rat. J.  Comp. Neurol. 253:175-184. 
Walicke, P. A.  1989.  Novel neurotrophic factors, receptors, and oncogenes. 
Annu.  Rev. Neurosci.  12:103-126. 
Zimmer, D. B., and L. J. Van Eldik.  1987.  Tissue distribution of rat SI00a 
and SI00/3 and Sl00-binding proteins. Am. J.  Physiol.  252:C285-C289. 
Zomzeley-Nenrath, C., and W. Walker.  1980.  Nervous system-specific pro- 
teins: 14-3-2 protein, neuron-specific enolase, and SI00 protein. In Proteins 
of the Nervous System. 2rid edition. R. A. Bradshaw, and D. M. Schneider, 
editors. Raven Press, New York.  1-57. 
Winningham-Major et al. Neurotrophic Activity of Recombinant SlOOs  3071 